<DOC>
	<DOCNO>NCT00811941</DOCNO>
	<brief_summary>The purpose study long-term safety , tolerability efficacy nalmefene patient alcohol dependence .</brief_summary>
	<brief_title>Safety Efficacy Nalmefene Patients With Alcohol Dependence</brief_title>
	<detailed_description>Alcohol dependence maladaptive pattern alcohol use , lead clinically significant impairment distress , manifest least three number criterion tolerance , withdrawal symptom , frequent use alcohol large amount longer period intend , others . Excessive intake alcohol reduce life span decade , alcohol drinking strongly relate mortality liver cirrhosis , chronic pancreatitis , certain cancer , hypertension , accident violence . This study plan evaluate long-term safety tolerability well evaluate efficacy need use 18.06 mg nalmefene patient alcohol dependence .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>In outpatient : primary diagnosis alcohol dependence accord Diagnostic Statistical Manual Mental Disorders text revision ( DSMIVTR ) criteria â‰¥6 Heavy Drinking Days ( HDDs ) 4 week precede Screening Visit The patient : severe psychiatric disorder antisocial personality disorder risk suicide evaluate suicidality module MiniInternational Neuropsychiatric Interview ( MINI ) history delirium tremens alcohol withdrawal seizure report current recent ( within 3 month precede screen ) treatment disulfiram , acamprosate , topiramate , naltrexone carbimide , opioid antagonist pregnant breastfeed Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Alcohol-Related Disorders</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>